Viking Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
VKTX$28.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated · Accumulated OtherComprehensive · Treasury Stock | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Gain (Loss) | Amount | Total | |
| Balance at December 31, 2022 | 78,257,258 | $1 | $445,267 | $(292,049) | $(1,102) | $(6,795) | $145,322 |
| Employee stock-based compensation, net | — | — | 16,750 | — | — | — | 16,750 |
| Shares withheld related to employee tax withholding | (509,686) | — | (7,121) | — | — | — | (7,121) |
| Issuance of common stock under employee stock plans | 2,359,694 | — | 6,768 | — | — | — | 6,768 |
| Sale of common stock, net of issuance costs | 20,006,504 | — | 271,882 | — | — | — | 271,882 |
| Unrealized gain on investments | — | — | — | — | 742 | — | 742 |
| Unrealized currency translation loss | — | — | — | — | (29) | — | (29) |
| Net Loss | — | — | — | (85,895) | — | — | (85,895) |
| Balance at December 31, 2023 | 100,113,770 | $1 | $733,546 | $(377,944) | $(389) | $(6,795) | $348,419 |
| Employee stock-based compensation, net | — | — | 29,712 | — | — | — | 29,712 |
| Shares withheld related to employee tax withholding | (541,876) | — | (42,101) | — | — | — | (42,101) |
| Issuance of common stock under employee stock plans | 3,133,672 | — | 10,813 | — | — | — | 10,813 |
| Sale of common stock, net of issuance costs | 8,867,953 | — | 637,002 | — | — | 6,795 | 643,797 |
| Unrealized loss on investments | — | — | — | — | (173) | — | (173) |
| Unrealized currency translation loss | — | — | — | — | (226) | — | (226) |
| Net Loss | — | — | — | (109,963) | — | — | (109,963) |
| Balance at December 31, 2024 | 111,573,519 | $1 | $1,368,972 | $(487,907) | $(788) | $— | $880,278 |
| Employee stock-based compensation, net | — | — | 40,818 | — | — | — | 40,818 |
| Issuance of common stock under employee stock plans | 1,088,940 | — | 2,491 | — | — | — | 2,491 |
| Sale of common stock, net of issuance costs | 2,130,608 | — | 73,948 | — | — | — | 73,948 |
| Unrealized gain on investments | — | — | — | — | 1,119 | — | 1,119 |
| Unrealized currency translation gain | — | — | — | — | 47 | — | 47 |
| Net Loss | — | — | — | (359,639) | — | — | (359,639) |
| Balance at December 31, 2025 | 114,793,067 | $1 | $1,486,229 | $(847,546) | $378 | $— | $639,062 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.